RIL
RAPP

Rothschild Investment LLC’s Rapport Therapeutics RAPP Stock Holding History

Rothschild Investment LLC’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$626 Buy
+20
New +$563 ﹤0.01% 3049

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Rothschild Investment LLC's RAPP Position: Q1 2026 in Review

Rothschild Investment LLC opened a new position in Rapport Therapeutics (RAPP) in Q1 2026: 20 shares worth $626. The stake represents ﹤0.01% of the portfolio and ranks #3049 among its holdings.

147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Rothschild Investment LLC held 20 shares of Rapport Therapeutics worth $626 as of Q1 2026.
  • Rapport Therapeutics was a new Rothschild Investment LLC position in Q1 2026.
  • Rapport Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3049 holding.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.